If you are seeing this message, you may be experiencing temporary network problems. Please wait a few minutes and refresh the page. If the problem persists, you may wish to report it to your local Network Manager.
It is also possible that your web browser is not configured or not able to display style sheets. In this case, although the visual presentation will be degraded, the site should continue to be functional. We recommend using the latest version of Microsoft or Mozilla web browser to help minimise these problems.
Wiley InterScience | ||
![]() RespirologyVolume 10 Issue 1, Pages 2 - 8 Published Online: 3 Feb 2005 Journal compilation © 2010 Asian Pacific Society of Respirology Published on behalf of Asian Pacific Society of Respirology
Abstract | References | Full Text: HTML, PDF (Size: 220K) | Related Articles | Citation Tracking INVITED REVIEW SERIES: PLEURAL DISEASES Pathogenesis of malignant pleural mesothelioma Copyright 2005 Blackwell Publishing Ltd KEYWORDS asbestos • mesothelioma • neurofibromatosis 2 • simian virus 40 • transgenic mice
Pathogenesis of malignant pleural mesothelioma
JAURAND M-C, FLEURY-FEITH J. Respirology 2005; 10: 2–8 ABSTRACTAbstract: Malignant pleural mesothelioma (MPM) results from neoplastic transformation of mesothelial cells. Past asbestos exposure represents the major risk factor for MPM, as the link between asbestos fibres and MPM has been largely proved by epidemiological and experimental studies. Asbestos fibres induce DNA and chromosome damage linked to oxidative stress following phagocytosis. Recently, simian virus 40 (SV40) has been implicated in the aetiology of MPM. The origin of human infection has been associated with SV40-contaminated polio vaccines, although to date, no epidemiological data supports this hypothesis. SV40 may act as a coactivator of asbestos in mesothelial oncogenesis. The transforming potency of SV40 results from the activity of two viral proteins, large T and small t antigens. SV40 infection stimulates production of growth factors elsewhere implicated in autocrine growth of mesothelioma cells and inactivates RASSF1, a gene silenced in MPM. Roles for ionising radiation, chemicals or genetic factors have also been suggested from the observation of sporadic MPM cases or animal studies. Genetic alterations in the tumour suppressor genes, P16/CDKN2A and neurofibromatosis 2 (NF2), are found both in human MPM and in asbestos-exposed Nƒ2-deficient mice. MPM is still of great international concern. Despite a ban on asbestos use in Western countries, the incidence of MPM is increasing, due to the long delay between asbestos exposure and diagnosis. Moreover, asbestos is still used in developing countries. The implication of other risk factors, especially SV40, supports a need for further research into MPM. Received 21 September 2004; revised 12 November 2004; accepted for publication 19 November 2004. |